LDS/Medical Tests/Comprehensive Mitochondrial Disorders Gene Analysis Panel, NGS (Genomic Unity®)

Comprehensive Mitochondrial Disorders Gene Analysis Panel, NGS (Genomic Unity®)

A mitochondrial gene mutation panel is used to detect mutations in nuclear DNA encoding mitochondrial proteins or in mitochondrial DNA. Mitochondrial genetic disorders affect the energy production systems in each cell of the body. These diseases can occur at any age and effect the brain, muscles, heart, liver, nerves, eyes, ears, and kidneys. As an individual’s mitochondria are derived from the maternal ova the disorders caused by mutations in mitochondrial DNA are either maternally inherited or arise de novo in the ova or embryo. The disorders caused by mutations in nuclear DNA may follow an autosomal dominant, autosomal recessive, or X-linked patterns of inheritance. Mitochondrial genetic disorders are estimated to effect 1 in 5,000–8,500 people. These disorders include: Kearns-Sayre syndrome, Pearson syndrome, Progressive external opthalmoplegia (PEO), Leber hereditary optic neuropathy, Myoclonic epilepsy with ragged-red fibers (MERRF), Mitochondrial encephalomyopathy lactic acidosis, and stroke-like episodes (MELAS), Maternally inherited diabetes and deafness (MIDD), Leigh syndrome, Mitochondrial neurogastrointestinal encephalopathy (MNGIE), among others. One of published panel is the comprehensive mitochondrial genomic disorders analysis by Genomic Unity®. this a NGS based genomic testing that can sequence 336 nuclear genes and diagnose diverse disorders caused by mitochondrial disorders. The assay detects different variations including SNPs, CMVs, indels, deletion/duplication, intronic variants, and inversions.

Kearns-Sayre syndrome (KSS) is a mitochondrial myopathy, due to large heteroplasmic deletions of mitochondrial DNA (mtDNA). The deletions range from 1,000 to 10,000 nucleotides, and the most common deletion is 4,997 nucleotides. The mtDNA deletion syndromes are almost never inherited and are instead caused by de novo mtDNA deletions occurring in maternal oocytes during germline development or in the embryo during embryogenesis. This disease is characterized by proximal muscle weakness, pigmented retinopathy, cardiac arrhythmia and ataxia. The mitochondrial DNA deletions result in the loss of genes that produce proteins required for oxidative phosphorylation, causing a decrease in cellular energy production.

Leber hereditary optic neuropathy (LHON) is characterized by a sudden, complete, painless loss of central vision caused by optic nerve atrophy. Typically, there is loss of vision in one eye followed by loss in the other eye. Some individuals with loss of central sight may also have cardiac conduction disorders, sensory and motor neuropathy, tremor, ataxia and basal ganglia damage. LHON symptoms may occur at any age, although most cases occur between the ages of 15 to 35 years. Men are disproportionately affected with a male: female ratio of 4:1. The majority of LHON cases (90%) are associated with point mitochondrial DNA mutations in one of the mitochondrial genes: MT-ND1, MT-ND4, MT-ND4L, or MT-ND6.

Myoclonic epilepsy with ragged-red fibers (MERRF) is a chronic neurodegenerative disease that manifests in both children and adults. This syndrome is diagnosed based on the cardinal features of; myoclonus, generalized epilepsy, ataxia, and ragged red fibers (RRF) in the muscle biopsy however, clinical features may also include dementia, cardiomyopathy, cardiac arrhythmias, neuropathies, pyramidal insufficiency, optic atrophy and sensorineural hearing loss. Most (80%) of MERRF cases are caused by a maternally inherited point mutation (8344A>G) in the MT-TK gene however, it may also result from mutations in MT-TL1, MT-TH, or MT-TS1. These mutations may impair the ability of mitochondria to make proteins, use oxygen, and produce energy

Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) is characterized by dilated or hypertrophic cardiomyopathy, excitation of Hiss bundles of nervous fibers (preexcitation, bundle branch block), stroke-like episodes, seizures and diabetes, it is most often diagnosed in early childhood or juvenile period. It is a neurodegenerative disease resulting from demyelination of the nerve fibers and gradual neuronal death. Additional symptoms of MELAS include sensorineural hearing loss, ptosis, epilepsy, muscle fatigue and pain, generalized myopathy, myalgia and severe headache. The majority of cases (80%) are due to inherited maternal mutations in the MT-TL1 gene although it may also be caused by mutations in MT-ND1, MT-ND5, MT-TH, or MT-TV. The mutations that cause MELAS impair the ability of mitochondria to make proteins, use oxygen, and produce energy.

Maternally inherited diabetes and deafness (MIDD) is characterized by sensorineural hearing loss and the development of diabetes in adulthood. MIDD can be accompanied by other symptoms of mitochondrial disorders: cardiomyopathy, myopathy, retinitis pigmentosa, ptosis, disorders of the renal tubules, and psychoneurological symptoms. MIDD is caused by mutations in mitochondrial genes; MT-TL1, MT-TK, or MT-TE. which impair protein production in mitochondria and disrupt their function.

Mitochondrial DNA-associated Leigh syndrome (LS) is an infantile subacute necrotizing encephalopathy transmitted by maternal mitochondrial inheritance. It is a progressive neurodegenerative disease affecting children characterized by physical and mental developmental disorders, disruption of previously acquired skills, delayed development, muscle weakness, problems with movement, or difficulty breathing. Clinical features of LS include perinatal asphyxia, respiratory dysfunction, neuropathies of cranial nerves, ataxia, dystonia, hypotension, seizures and disturbances of reflex activity, in particular, sucking and swallowing reflexes. Most cases of LS are caused by mutations in the MT-ATP6 gene which may cause impairment of oxidative phosphorylation leading to cell death in sensitive tissues. Rarely mutations in MT-ND3, MT-ND5 or MTND6 have been associated with LS.

Neuropathy, ataxia, and retinitis pigmentosa (NARP) usually manifests in the second decade of life and in contrast to LS, the disease progresses much slower. The characteristic symptoms of NARP are proximal muscle weakness, sensory neuropathy, ataxia, cardiomyopathy, developmental delay, learning problems, degeneration of the retina, dementia and seizures. Like Leigh syndrome, NARP is caused by mutations in MT-ATP6 that alter the structure or function of ATP synthase, reducing the ability of mitochondria to make ATP.

Patients with mutations in mitochondrial genes MT-RNR1 or MT-TS1 may be at increased risk for aminoglycoside-induced hearing disorders. The use of gentamicin, tobramycin, amikacin, kanamycin, or streptomycin, even once, in these individuals can lead to a bilateral hearing loss of varying severity. Mutation in the MT-RNR1 gene makes the 12S RNA in human cells mimic bacterial ribosomal RNA and as a result, it is targeted by aminoglycosides impairing the ability of mitochondria to produce proteins needed for oxidative phosphorylation. MT-TS1 gene mutations are likely to disrupt the normal production of the tRNASer(UCN) molecule or alter its structure. As a result, less tRNASer(UCN) is available to assemble proteins within the mitochondria reducing oxidative phosphorylation, which impairs the ability of mitochondria to make ATP.

Panel Components

Although it depends on the laboratory and the clinical utility comprehensive panels like this uses targeted next-generation sequencing to evaluate for most common variants within genes: AARS2, AASS, ABAT, ABCB7, ACACA, ACAD9, ACO2, AFG3L2, AGK, AIFM1 ALDH3A2, AMPD1, APOPT1, APTX, ATP5A1, ATP5E, ATP5G3, ATPAF2, AUH, BCS1L, BOLA3, C12orf65, CA5A, CHAT, CLPP, COA5, COA6, COQ2, COQ4, COQ6, COQ8A (ADCK3), COQ8B (ADCK4), COQ9, COX10, COX14, COX15, COX20, COX4I2, COX6B1, COX7B, CYC1, D2HGDH, DARS2, DGUOK, DLAT, DLD, DNA2, DNAJC19, DNM1L, EARS2, ELAC2, ETFA, ETFB, ETFDH, ETHE1, FARS2, FASTKD2, FBXL4, FH, FOXRED1, FXN, GAMT, GARS, GCDH, GFER, GFM1, HARS2, HIBCH, IARS2, IBA57, IDH2, ISCU, L2HGDH, LARS2, LIAS, LRPPRC, LYRM4, LYRM7, MARS2, MGME1, MICU1, MPC1, MPV17, MRPL3, MRPL44, MRPS16, MRPS22, MTFMT, MTO1, MTPAP, NDUFA1, NDUFA10, NDUFA11, NDUFA12, NDUFA2, NDUFA9, NDUFAF1, NDUFAF2, NDUFAF3, NDUFAF4, NDUFAF5, NDUFAF6, NDUFB3, NDUFB9, NDUFS1, NDUFS2, NDUFS3, NDUFS4, NDUFS6, NDUFS7, NDUFS8, NDUFV1, NDUFV2, NFU1, NUBPL, OGDH, OPA1, OPA3, OXCT1, PANK2, PC, PCK2, PDHA1, PDHB, PDHX, PDP1, PDSS1, PDSS2, PNKD, PNPT1, POLG, POLG2, PUS1, RARS2, RMND1, RRM2B, SACS, SARS2, SCO1, SCO2, SDHAF1, SERAC1, SFXN4, SLC19A3, SLC25A1, SLC25A12, SLC25A19, SLC25A3, SLC25A4, SLC52A2, SUCLA2, SUCLG1, SUGCT, SURF1, TACO1, TARS2, TAZ, TIMM44, TIMM8A, TK2, TMEM126A, TMEM70, TPK1, TRAP1, TRMU, TSFM, TTC19, TUFM, TWNK (C10orf2), TYMP, UQCRB, UQCRC2, UQCRQ, VARS2, XPNPEP3, and YARS2 genes associated with mitochondrial genetic disorders.

  • For the diagnosis of disorders caused by mutations in the mitochondrial genome
  • To confirm a diagnosis of a suspected mitochondrial genetic disorders such as Kearns-Sayre syndrome, Leber hereditary optic neuropathy, Myoclonic epilepsy with ragged-red fibers, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, Maternally inherited diabetes and deafness, Leigh syndrome, aminoglycoside-induced hearing disorders
  • For pre-conception planning for potentially at-risk individuals
  • For pre-implantation embryonic testing in potentially at-risk individuals
  • To help for predictive testing of at-risk family members and determine which relatives are at risk
At least one known pathogenic variant or mutation (deletion or duplication) associated with mitochondrial genetic disorders should be detected. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants.

Negative for mutations (deletion or duplication) or pathogenic variants in the genes tested

Next Generation Sequencing (NGS), Sanger Sequencing.

Whole blood (EDTA), Cultured fibroblasts, skin biopsy, Tissue biopsy.

Stability

Whole blood, Cultured fibroblasts 

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days

Skin biopsy and tissue biopsy fixed in formalin (FFPE) are stable for longer in room temperature. 

Muscle biopsy, Lactate levels in blood and CSF, Plasma citrulline levels, Plasma amino acids analysis, Urine organic acid analysis, Respiratory chain enzyme analysis.
2-4 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login